Bank of New York Mellon
NVLN

Bank of New York Mellon’s Novelion Therapeutics Inc. Common Shares NVLN Stock Holding History

Bank of New York Mellon’s Portfolio NVLN Stock Details NVLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-38,799
Closed -$136K – 4362
2018
Q1 		$136K Sell
38,799
-1,050
-3% -$4.45K ﹤0.01% 4003
2017
Q4 		$125K Buy
39,849
+1,077
+3% +$5.18K ﹤0.01% 4040
2017
Q3 		$272K Sell
38,772
-2,398
-6% -$19.2K ﹤0.01% 3786
2017
Q2 		$380K Buy
+41,170
New +$396K ﹤0.01% 3721

Other funds holding NVLN

EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $320M AUM 140.1% 1-Year Est. Return

Bank of New York Mellon's NVLN Position: Q2 2018 in Review

Bank of New York Mellon sold out of Novelion Therapeutics Inc. Common Shares (NVLN) in Q2 2018, closing a stake of 38,799 shares — an estimated $136K sold.

Bank of New York Mellon first reported a position in NVLN in Q2 2017 and held it in 4 quarters. The position peaked at $380K in Q2 2017. 53 funds tracked by Wall St. Rank hold NVLN as of Q2 2018.

  • Bank of New York Mellon reported no remaining Novelion Therapeutics Inc. Common Shares position as of Q2 2018 after selling out during the quarter.
  • Bank of New York Mellon sold 38,799 Novelion Therapeutics Inc. Common Shares shares in Q2 2018, an estimated $136K.
  • Bank of New York Mellon first reported a position in Novelion Therapeutics Inc. Common Shares in Q2 2017 and held it in 4 quarters.
  • Bank of New York Mellon's Novelion Therapeutics Inc. Common Shares position peaked at $380K in Q2 2017.
  • 53 funds tracked by Wall St. Rank held Novelion Therapeutics Inc. Common Shares as of Q2 2018.

Based on Bank of New York Mellon's 13F filing for Q2 2018, filed 6 Aug 2018.